Prenetics Global Limited (PRE)
| Market Cap | 309.98M |
| Revenue (ttm) | 92.39M |
| Net Income (ttm) | -58.32M |
| Shares Out | 16.83M |
| EPS (ttm) | -4.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,492 |
| Open | 19.47 |
| Previous Close | 19.62 |
| Day's Range | 17.90 - 19.57 |
| 52-Week Range | 5.00 - 23.63 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 30.50 (+65.58%) |
| Earnings Date | Jun 11, 2026 |
About PRE
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions. Pren... [Read more]
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 201.72% compared to the previous year's $30.62 million. Losses were -$58.32 million, 26.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 65.58% from the latest price.
News
Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and ...
Prenetics Global Transcript: The 38th Annual Roth Conference
Panelists from leading wellness and consumer brands discussed the importance of authentic influencer partnerships, emphasizing that genuine product use, equity alignment, and scientific validation drive long-term success. Data-driven tracking, multi-year deals, and a mix of macro and micro-influencers were highlighted as best practices.
Prenetics Global Transcript: The 38th Annual Roth Conference
IM8 has rapidly scaled to $100 million ARR in under a year by focusing on a unique all-in-one supplement, leveraging celebrity ambassadors, and a robust direct-to-consumer model. Strong retention, global reach, and aggressive digital marketing—powered by AI—support ambitious growth targets and new product launches in 2026.
Prenetics Global Transcript: Sidoti March Small-Cap Virtual Conference
IM8 drove explosive growth, reaching $120 million ARR in its first year and fueling a strategic focus on global DTC expansion. With robust liquidity, premium products, and strong ambassador partnerships, the brand projects $180–$200 million revenue in 2026 and aims for profitability by Q4 2027.
Prenetics Global Earnings Call Transcript: Q4 2025
Record 2025 revenue of $92.4M, up 480% year-over-year, driven by IM8's explosive growth and global expansion. Strategic divestitures strengthened liquidity to $171M with no debt. 2026 guidance targets $180M-$200M IM8 revenue and 60% gross margin, with profitability expected by Q4 2027.
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced on February 18, 2026 NEW YORK, F...
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and l...
Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Lim...
Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced...
Prenetics Global Transcript: Sidoti Micro-Cap Virtual Investor Conference
IM8, co-founded with David Beckham, has become the fastest-growing supplement brand, reaching $120 million ARR in under a year and projecting $180–$200 million revenue for 2026. With strong financials, global expansion, and high-profile ambassadors, the company is positioned for continued rapid growth.
Buying bitcoin is no longer a thing for this David Beckham-backed health company
Talk about an about-face. What Prenetics Global once a called a long-term, “unprecedented commitment” to bitcoin has gone by the wayside in just six months.
Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure
CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and lon...
Prenetics Global Transcript: Sidoti's Year End Virtual Investor Conference
IM8, a premium supplement brand, has achieved $100 million ARR in 11 months and projects $180-$200 million in 2025 revenue, driven by global direct-to-consumer sales and high-profile ambassadors. The company is divesting legacy assets to focus on IM8, maintains a strong balance sheet, and employs a Bitcoin treasury strategy.
Prenetics Announces Upcoming Conference Participation
CHARLOTTE, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and lon...
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8 and a global health-tech and longevity company pione...
Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
IM8's Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial Posi...
Prenetics Global Earnings Call Transcript: Q3 2025
Q3 saw revenue surge 568% year-over-year to $23.6M, driven by IMA's rapid global expansion and 76% sequential growth. Gross margin rose to 60%, and adjusted EBITDA loss narrowed to $2.1M, with strong liquidity and no debt supporting aggressive scaling.
Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History
Total Revenue Surges 568% YoY to $23.6 million ; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Mont...
Prenetics' IM8 Achieves Record $9 Million in Revenue for October, Surpasses $108 Million in Annualized Recurring Revenue 11 Months After Launch
~ October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 ~ CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (Nasdaq: PRE) (“Preneti...
Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$46 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prene...
Prenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth
Comprehensive Document Reveals Strategic Vision Behind Company's Unprecedented Growth and Bitcoin Treasury Strategy IM8, the Fastest-Growing Supplement Brand in Industry History, Reaching Reaches $100...
Prenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy
CHARLOTTE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the closing of its previous...
Prenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy
Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE: EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions
Prenetics' IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging
Launch Follows IM8's Record Growth to $6.6 Million Monthly Revenue in September IM8 Accelerates Toward $100 Million ARR Milestone with One of the Industry's Fastest Growth Rates CHARLOTTE, N.C., Oct. ...
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
- Keynote: “IM8: The World's Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sep...